TRAX Reports Positive Celiac Study Results; MIRM Meets Phase 3 Endpoint
Premarket mover roundup also includes TRMD’s full-year guidance upgrade, talk of advanced sale talks involving CCC, and BMY’s positive interim Phase 3 ACTION-1 results. The source also cites analyst upgrades for CRM, BIIB and FSLR, plus a DHT business update.